<DOC>
	<DOCNO>NCT00966810</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation , know curative modality CML , abandon recent year effective much less toxic target therapy tyrosine kinase inhibitor ( TKIs ) . However , approximately one third patient still need another treatment include stem cell transplantation . The study protocol comprise cohort consecutive patient CML receive allogeneic stem cell transplantation use partial T cell depletion , post-transplant GvHD prophylaxis . Forty consecutive patient CML underwent allogeneic stem cell transplantation match sibling use partial T cell depletion ( TCD ) , single institution . Escalated dose donor lymphocyte infusion ( DLI ) give case either relapse presence minimal residual disease ( MRD ) detect cytogenetic molecular analysis . The purpose study decrease transplant-related toxicity .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation CML With Partial T Cell Depletion</brief_title>
	<detailed_description>Patients condition oral busulfan 12mg/kg ( day -6 -4 ) , cyclophosphamide 120mg/kg ( day -3 , -2 ) , rabbit antithymocytic globulin , ( Fresenius , Bad Hamburg , Germany ) 25mg/kg ( day -5 -1 ) fludarabine 200 mg/kg ( day -7 to-3 ) . Final busulfan dose individually determine base measurement serum busulfan level target dose 850-1400 microM x minute . Transplants perform reverse isolation room equip high-efficiency particulate air filtration system ( HEPA ) . No post-transplant GvHD prophylaxis give . Post-transplant infection prophylaxis consist acyclovir , itraconazole , trimethoprim-sulfamethoxazole penicillin VK . Cytomegalovirus ( CMV ) status determine weekly use PCR CMV-DNA pp65 antigenemia blood leukocyte , follow preemptive ganciclovir administration positive . Donors Donors human leukocyte antigen ( HLA ) A , B , C serologically match DR DQ molecularly match sibling . Donor stem cell collect follow mobilization 10 µg/kg/day G-CSF , give subcutaneously 5 consecutive day . CD34 cell positively select use anti-CD34 antibody conjugate iron-dextran microbeads use CliniMACS device ( Miltenyi Biotech , Bergisch Gladbach , Germany ) aim collect &gt; 5.0 x 106 CD34 cells/kg . Disease monitor Following transplant , patient close surveillance presence minimal residual disease ( MRD ) use cytogenetic analysis PCR detection BCR/ABL transcript . Bone marrow peripheral blood sample examine every 3 month first year post transplant every 3-6 month subsequent year . PCR method : RQ-PCR perform accord Europe Against Cancer ( EAC ) protocol.19 The BCR-ABL ABL copy number calculate compare standard curve generate use IPSOGEN FusionQuant Standards . The result quantify BCR-ABL transcript express percentage ratio relative total ABL transcript . A minimum number 1x104 copy ABL low limit negative RT-PCR consider unreliable . In molecular biology laboratory Rambam Health Care Campus sensitivity quantitative Q-PCR ( 10-5 ) . Donor leukocyte infusion ( DLI ) . DLI administer escalate dose regimen start 3 x 106 cells/kg follow necessary 1 x 107 cells/kg , 5 x 107 cells/kg 1 x 108 cells/kg . DLI use case persistence/reappearance BCR-ABL transcript start 6 month post transplant onward . In instance 1 DLI administer successive escalate dose give ≥ 3-month interval dictate MRD follow-up .</detailed_description>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Diagnosis chronic phase CML hematological , cytogenetic molecular study . Age &gt; 18 Candidates allogeneic stem cell transplantation Available match related donor Age &lt; 18 year Other malignancy Decreased cardiac function ( echo ) , reduce pulmonary function ( decreased DLCO , FEV1 ) , abnormal kidney function ( creatinine &gt; 1.5 N ) , abnormal liver function ( AST , ALT &gt; 2N )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>chronic myelocytic leukemia</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>T cell depletion</keyword>
	<keyword>donor lymphocyte infusion</keyword>
	<keyword>GvHD</keyword>
	<keyword>transplant relate mortality</keyword>
</DOC>